129506-80-5

Upstream product

• 62667-42-9 4-vinyl(phenyl)acetic acid methyl ester 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 67-56-1 methanol 
• 17833-56-6 ester monomethylique de l'acide p-phenylene diacetique 

Downstream Products

• 78712-65-9 methyl 4-(2-bromoethyl)phenylacetate 

Relevant academic research and scientific papers

Nitroxide derivative of ROCK kinase inhibitor

The invention provides a small molecular compound of a NO donor. The small molecular compound is characterized in that the small molecular compound is a compound shown represented by structural formula I shown in the description, or a stereoisomer, a geometrical isomer, a tautomer, a racemate, a deuterated isotope derivative, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof; and in the formula I, ring A is a substituted or unsubstituted heteroaromatic ring, X is selected from (CH2)n, n is selected from 0, 1, 2 and 3, R is a substituent group of terminal -O-NO2, R is selected from hydrogen, a hydroxyl group, halogen, an amino group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group and a substituted or unsubstituted heteroalkyl group, and R and R are respectively and independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted naphthenic base or an amino protecting group, or R and R are connected to form a substituted or unsubstituted cyclic heteroalkyl group. The compound has a high-activity inhibition effect on ROCK kinase.

Method for preparing compared to the Russ sandbank

The invention provides a preparation method of bilastine. The preparation method of bilastine comprises the following steps: converting a compound with a structure shown as a formula (II) to a compound with a structure shown as a formula (III), and then h

Muscarinic receptor antagonists

Compounds of the formula I STR1 wherein X, Y and v are as defined below, novel intermediates used in their synthesis, and the pharmaceutically acceptable salts of such compounds and intermediates. The compounds of formula I and the novel intermediates used in their synthesis are muscarinic receptor antagonists that are selected for smooth muscle muscarinic sites and are useful in the prevention and treatment of diseases associated with altered motility or tone of smooth muscle, such as irritable bowel syndrome, diverticular disease, urinary incontinence, aesophageal achalasia, and chronic obstructive airways disease.

Muscarinic receptor antagonists

A compound of the formula (IA) or (IB), useful in treating diseases associated with the altered motility and/or tone of smooth muscle, such as irritable bowel syndrome, of the formula:- and their pharmaceutically-acceptable salts, where Y is-CH?CH?-,-CH=CH-,-CH?-S-,-CH?-O-,-O-or-S-; and X is a group of the formula:- wherein m is 1 or 2; R1 and R2 are each independently H or C?-C? alkyl or together represent-(CH?)n-where n is an integer of from 2 to 5; R3 is H or C?-C? alkyl; Z is a direct link,-CH?-,-(CH? )?-,-CH?O-or-CH?S-; and R? is pyridyl, pyrazinyl, thienyl or a group of the formula:- where either R? and R? are each independently selected from H, C?-C? alkyl, C?-C? alkoxy, halo,-CF?,-CN,-(CH?) pNR? R?,-OCO(C?-C? alkyl),-CO(C?-C? alkyl),-CH(OH)(C?-C? alkyl),-C(OH) (C?-C? alkyl)?,-SO?NH?,-NHSO?(C?-C? alkyl),-(CH?)pOH,-(CH?)p COO(C?-C? alkyl),-(CH?)pCONR? R?, or R? and R? together represent-(CH?)q-,-O(CH?) rO-or-O(CH? )t-where in the latter the oxygen atom is attached to the 3-or 4-position of the benzene ring; R? and R? are each independently H or C?-C? alkyl; p is 0, 1 or 2; q is 3, 4 or 5; r is 1, 2 or 3; and t is 2, 3 or 4.